Releases Details

Notice of AGM

Sep 19, 2016

Released : September 19, 2016 17:00

RNS Number : 2422K
MaxCyte, Inc.
19 September 2016




MaxCyte, Inc.

("MaxCyte" or the "Company")


Notification of Annual General Meeting


Maryland, USA - 19 September 2016: MaxCyte (LSE: MXCT), the developer and supplier of cell engineering technology to biotechnology and pharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology, announces that formal notice and resolutions of the Company's AGM, along with the Annual Meeting Proxy Card, has been circulated to Shareholders.


These documents are also available in electronic form on the Company's website:


The Annual General Meeting of Stockholders is planned to be held on 26 October 2016 at 22 Firstfield Road, Suite 110, Gaithersburg, MD 20878 USA.



For further information please contact:



+1 301 944 1660

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Financial Officer

Nominated Adviser and Broker

Panmure Gordon

Freddy Crossley (Corporate Finance)

Fabien Holler

Duncan Monteith

Tom Salvesen (Corporate Broking)

+44 (0) 20 7886 2500


Financial PR Advisor

Consilium Strategic Communications

+44 (0)203 709 5700

Mary-Jane Elliott

Chris Welsh

Lindsey Neville


About MaxCyte


MaxCyte is an established and revenue generating US-based developer and supplier of cell engineering products and services to biopharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology markets, which independent market analyses estimate to be, in aggregate, in excess of $35 billion in 2015. The Company's patented flow electroporation technology enables its products to deliver fast, reliable and scalable cell engineering to drive the research and clinical development of a new generation of medicines.


MaxCyte's high performance platform allows transfection with any molecule or multiple molecules and is compatible with nearly all cell types, including hard-to-transfect human primary cells. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large scale, clinical and commercial grade cell engineering in a non-viral system and with low toxicity concerns. The Company's cell engineering technology platform is CE-marked and FDA-accredited, providing MaxCyte's customers and partners with an established regulatory path.


Using the unique capabilities of its technology, MaxCyte is developing CARMA, its proprietary platform in immuno-oncology, to deliver a validated non-viral approach to CAR therapies across a broad range of cancer indications, including solid tumors where existing CAR-T approaches face significant challenges.


For more information visit 

This information is provided by RNS
The company news service from the London Stock Exchange